AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03255057 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive mechanical ventilation
Description: Lung support for acute lung failure applied with a mechanical ventilation device that uses positive pressure to mechanically inflate the lungs and facilitate exhalation via an endotracheal tube or tracheotomy.
Study NCT03356171 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac Coherence
Description: * 10 sessions of HRV-BF (45mn) weekly over 12 weeks. HRV-BF is a cognitive behavioural therapy consisting on stress management training based on breathing. We use the SYMBIOLINE PC software to record the heart rate variability biofeedback, with an infrared plethysmograph sensor. The sensor is put on the finger, and the patient's HRV pattern is displayed in real time.~* 24 APA sessions (1.5h) bi-weekly over 12 weeks. Each session includes aerobic exercises (walk, step) and resistant exercises (muscular reinforcement). This program is built on previous cancer studies to make it effective.
Study NCT03356171 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Physical Activity
Description: - 24 APA sessions (1.5h) bi-weekly over 12 weeks. Each session includes aerobic exercises (walk, step) and resistant exercises (muscular reinforcement). This program is built on previous cancer studies to make it effective.
Study NCT02169817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus clausii
Description: Pharmaceutical form:aqueous suspension Route of administration: oral
Study NCT02169817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Therapy
Description: Pharmaceutical form:vials/sachets for solution Route of administration: oral
Study NCT02320136 — intervention group
Intervention type: BEHAVIORAL
Intervention: cognitive testing
Description: patients perform simple tasks like watching a video or memorizing items
Study NCT03518138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q-122
Description: oral capsule of Q-122
Study NCT03518138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule of placebo
Study NCT02952040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1517
Description: Oral dose
Study NCT02952040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate hydrate
Description: Oral dose
Study NCT01839253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: b-blocker(Atenolol)
Study NCT01839253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE inhibitor(Enapril)
Study NCT01839253 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Study NCT01756469 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention for Alcohol Use
Description: Behavioral Intervention for Alcohol Use
Study NCT00729781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyester Implants
Description: Three polyester (PET) implants will be implanted in each side of the nose affected by external NVC. See the detailed description for information about the implant procedure.
Study NCT03426826 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: FMT versus placebo
Description: Biological/Vaccine: Fecal Microbial Transplant versus placebo Fecal Transplant via endoscopy.~Other Names:~FMT
Study NCT03426826 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FMT versus placebo
Description: Biological/Vaccine: Fecal Microbial Transplant versus placebo Fecal Transplant via endoscopy.~Other Names:~FMT
Study NCT03512691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information on CVD Risk
Description: Respondents will be provided three types of information on CVD risks: a CVD base rate, a personalized CVD risk and an optimal CVD risk. The CVD base rate will be predicted from the respondent's age and sex only. After reporting their own chance of having a heart attack or stroke within ten years, the respondents in the treatment group will be told the risk for someone with the same age, sex, smoking status, body mass index (BMI) and blood pressure as them. Finally, a treatment group respondent will receive information on what the 10-year CVD risk would be for someone of the same age and gender who did not smoke, and had normal blood pressure and BMI.
Study NCT03512691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery Incentive
Description: Respondents will simply be told that they can enter a lottery if they go to the specified clinic for a checkup. The health facilities will be told to conduct an assessment deemed appropriate for any particular patient that requests to be issued with a lottery ticket. No instructions will be given that the facilities should follow the PhilPEN protocol. We will evaluate whether they do implement the protocol for patients who qualify (by age if nothing else) for full risk screening.
Study NCT02137122 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Administer 30 seconds of 2 mA electrical current to the head through saline soaked electrodes.
Study NCT02137122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Participants will undergo 20 minutes of 2 mA electrical stimulation to the head through saline soaked electrodes.
Study NCT03514030 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum AQP4-antibody testing method
Description: there are different methods of testing serum AQP4-antibody
Study NCT01606020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sleep deprivation
Description: Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep.
Study NCT01606020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Overnight, the subjects stay in their homes. No intervention during this night
Study NCT03579082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given ivgtt
Study NCT00789750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Description: Colesevelam 625 mg tablets
Study NCT00789750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets appearing to be colesevelam
Study NCT00789750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 30 mg or 45 mg pioglitazone therapy
Study NCT00789750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone
Description: 30 mg or 45 mg pioglitazone therapy
Study NCT02339064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apomorphine infusion
Description: Treatment with apomorphine provided by continuous subcutaneous infusion using a portable external electronic pump device
Study NCT00686270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apricitabine
Description: Initially 1200mg apricitabine twice daily orally. Following the determination of the optimum dose (800mg or 1200mg twice daily) in the pre-ceeding study AVX-301,patients may be switched to the optimum dose,if required.
Study NCT02959749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: 80 mg oral daily; until disease progression, intolerable toxicities, or patient death.
Study NCT02959749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel, bevacizumab
Description: Docetaxel and bevacizumab are common used in third line therapy in non-small cell lung cancer if not used before. Docetaxel (75 mg/m2) intravenous infusion on day 1 and bevacizumab (7.5 mg/kg) on day 1 every 21days a cycle, until disease progression, intolerable toxicities, or patient death.
Study NCT03512639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Homeopathic Medication
Description: Homeopathic medication (Arnica montana and the Bellis perennis) were given to women in the study group following mastectomy and reconstruction to reduce post operative seroma
Study NCT03512639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo was given to women in the control group following mastectomy and reconstruction to reduce post operative seroma
Study NCT03027375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishen Granules
Description: The QSG are manufactured by Beijing tcmages Pharmaceutical Co., Ltd. (Beijing, China), a company that has obtained Chinese Good Manufacturing Practice for Pharmaceutical Products certification. All the ingredients have been approved by the Chinese Ministry of Food and Drug Safety. 13.6 grams (dry weight) of granules consist of six herbs: Astragalus membranaceus (Fisch.) Bge. var. Mongolicus (Bge.) Hsiao (6g), Salvia miltiorrhiza Bge. (1.5g), Lonicera japonica Thunb. (2g), Scrophularia ningpoensis Hemsl. (2g), Aconitum carmichaeli Debx. (0.9g), and Glycyrrhiza uralensis Fisch. (1.2g).
Study NCT03027375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is manufactured by Beijing tcmages Pharmaceutical Co., Ltd. (Beijing, China) as well, following the Specification for processing Chinese medicine in Beijing. The placebo granules are similar in appearance, taste, and scent to the Qishen granules.
Study NCT02194036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning Oriented Physiotherapy
Description: Clinical practice based on a new understanding of the neurobiological basis for the interaction between body and mind, the foundation of learning and what is needed to bring about change of behavior.
Study NCT02194036 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Widely Recognized Psychiatric Treatment
Description: Standard recognized psychiatric treatment tailored to individual needs.
Study NCT00587392 — intervention group
Intervention type: DEVICE
Intervention: NDO Full-thickness Plicator
Description: The NDO Full-thickness Plicator intervention was performed as part of the original open-label Plicator study as previously reported. This intervention did not take place as part of this long-term follow-up data collection study.
Study NCT00783068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipopolysaccharide E. Coli 113:H 10:K negative
Description: Subjects will be randomized to oral pre-treatment with GTS-21 (150 mg tid 3 days before LPS injection and an oral dose of 150 mg GTS-21 on the morning of the day of the experiment (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0). One hour after ingestion of the last dosage of the study drug, purified LPS prepared from E coli O:113 (2 ng/kg iv) will be injected intravenously.
Study NCT00783068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipopolysaccharide E. Coli 113:H 10:K negative
Description: Subjects will be randomized to oral pre-treatment with GTS-21 (150 mg tid 3 days before LPS injection and an oral dose of 150 mg GTS-21 on the morning of the day of the experiment (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0). One hour after ingestion of the last dosage of the study drug, purified LPS prepared from E coli O:113 (2 ng/kg iv) will be injected intravenously.
Study NCT01487343 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaire and interview
Description: Interviews will be conducted with the first 10 participants who agree to be interviewed (or until data saturation is reached). Self-report questionnaires assessing adherence, beliefs about medications, side effect experience, self-efficacy, and satisfaction with patient education; the qualitative portion is an interview guided by two open-ended questions. Data will be collected approximately 2 weeks - 6 months (2 - 24 weeks) after being prescribed capecitabine.
Study NCT01910363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A2NTX
Description: Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
Study NCT01910363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX
Description: Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
Study NCT01815970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: 8 weeks of Pulmonary Rehabilitation including exercise and COPD related education.
Study NCT04592302 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw
Description: 2-4 weeks before surgery a blood draw will be taken to test for nicotine levels in the body
Study NCT02046577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Cholecalciferol administration
Study NCT04087278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red Raspberry Ellagitannin Extract
Description: Purified red raspberries ellagitannins extract 560 mg (4 capsules/day)
Study NCT04087278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo treatment matching intervention (no ellagitannin) 560 mg (4 capsules/day)
Study NCT01483833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iferanserin
Description: Iferanserin 0.5% ointment applied intra-anally twice daily for 14 days
Study NCT01483833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ointment applied intra-anally twice daily for 14 days
Study NCT03461874 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education of patients
Description: During withdrawal treatment, patients are given recommendations on the approach to the use of drugs for acute treatment of migraine headache and on lifestyle issues. With regard to drugs, patients will be encouraged to restrict use of acute medications to headaches with severe pain; i.e., those rated as 8 or greater on a 0-10 (no pain - pain as bad as it could be). In these instances, patients will be instructed to take Eletriptan (40 mg) and/or Almotriptan (12.5 mg) as the first-line treatment, indomethacin (50 mg) as the second line, and will be specifically urged to avoid opioids. With regard to healthy lifestyle issues, patients will be encouraged to engage in moderate physical activity (i.e., 45 minutes twice per week of aerobic exercise), remain well hydrated, consume 3 meals per day, and maintain a regular sleep/wake pattern with at least 7-8 hours of sleep per night.
Study NCT03461874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education of patients
Description: During withdrawal treatment, patients are given recommendations on the approach to the use of drugs for acute treatment of migraine headache and on lifestyle issues. With regard to drugs, patients will be encouraged to restrict use of acute medications to headaches with severe pain; i.e., those rated as 8 or greater on a 0-10 (no pain - pain as bad as it could be). In these instances, patients will be instructed to take Eletriptan (40 mg) and/or Almotriptan (12.5 mg) as the first-line treatment, indomethacin (50 mg) as the second line, and will be specifically urged to avoid opioids. With regard to healthy lifestyle issues, patients will be encouraged to engage in moderate physical activity (i.e., 45 minutes twice per week of aerobic exercise), remain well hydrated, consume 3 meals per day, and maintain a regular sleep/wake pattern with at least 7-8 hours of sleep per night.
Study NCT03461874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: ACT consists in 6 weekly sessions, 90 minutes each, and 2 supplementary booster sessions, at two and four weeks after the conclusion of the weekly session. The main focus of the six ACT session will be the following: 1) Creative helplessness: the problem of control; 2) Indentifying values: introduction to Mindfulness; 3) Actions guided by values: working with thought; 4) Working with Acceptance and Willingness; 5) Committed Actions: self-as-context; 6) Integration: working with obstacles - wrap-up. The booster session starts with a mindfulness exercise, followed by a review of the contents covered across the ACT program.~Patients will be trained in small groups (5-7 patients each) and guided by a specifically trained therapist. They will be educated to practice at home according to the instructions given by the therapist during the sessions.
Study NCT03461874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological prophylaxis
Description: Pharmacological prophylaxis will be prescribed based on patients' profile (e.g. previous failures or contraindications), and limited to Topiramate, Propanolol, Amytriptiline or Flunarizine. Doses will depend on patients' features, and the doses herein reported are to be intended as approximate ones: Topiramate at the dose of 50mg/day; Propanolol at the dose of 20mg/day; Amytriptiline at the dose of 10mg/day; Flunarizine at the dose of 5mg/day.
Study NCT03461874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacological prophylaxis
Description: Pharmacological prophylaxis will be prescribed based on patients' profile (e.g. previous failures or contraindications), and limited to Topiramate, Propanolol, Amytriptiline or Flunarizine. Doses will depend on patients' features, and the doses herein reported are to be intended as approximate ones: Topiramate at the dose of 50mg/day; Propanolol at the dose of 20mg/day; Amytriptiline at the dose of 10mg/day; Flunarizine at the dose of 5mg/day.
Study NCT01106820 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised progressive resistance training
Description: Supervised progressive resistance training
Study NCT01106820 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised progressive muscle relaxation training (Jacobsen method)
Description: Supervised progressive muscle relaxation training (Jacobsen method)
Study NCT02681250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Titanium-zirconium
Description: Titanium-zirconium implants will be installed according to the protocol earlier described in the detailed description.
Study NCT02681250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium
Description: Titanium implants will be installed according to the protocol earlier described in the detailed description.
Study NCT03057314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amorphous Calcium Carbonate
Description: Subjects will be administered with:~1. ACC tablets, containing 200 mg elemental calcium~2. 1% ACC (i.e. 0.3% calcium) + 5 mL Water for Injection, as a sterile suspension
Study NCT04195581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A
Description: Subjects were randomized to wear each lens and solution combination for a month.
Study NCT04195581 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fanfilcon A
Description: Subjects were randomized to wear each lens and solution combination for a month.
Study NCT01584076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Oral Donepezil Daily~Initial Dosage: Donepezil 5 mg tablets will be used. 1/2 tablet (≈2.5 mg)/day for 8 to 17 year olds OR 1 tablet (5 mg)/day for ≥18 year olds.~Dosage Escalation: Donepezil may be increased by 1/2 tablet (≈2.5 mg)/day every 4 weeks if the amblyopic eye visual acuity has not improved by ≥5 letters or 1 logMAR line to a maximum dosage of 1 1/2 tablets (≈7.5 mg)/day for 8 to 17 year olds OR 2 tablets (10 mg)/day for ≥18 year olds.
Study NCT01584076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patching
Description: Patching: 2 hours of daily patching will also be prescribed for 8 to 17 year olds only.
Study NCT03623581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB226
Description: 3mg/kg treat every 2 weeks
Study NCT01883479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Telephone-based intervention designed to increase exercise among postpartum women.
Study NCT01883479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness/Support
Description: Telephone-based intervention designed to provide support to postpartum women.
Study NCT00457873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% saline in 5% dextrose (intravenous)
Study NCT00457873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.45% saline in 5% dextrose (intravenous)
Study NCT02367066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-C165395XX
Description: Oral dose of AR-C165395XX (tablets)
Study NCT02367066 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose of placebo for AR-C165395XX (tablets)
Study NCT04616391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insulin pump Medtronic 780G
Description: Patients from the AHCL group will use the MiniMed 780G AHCL system. This system is already CE-marked.~The AHCL system will be initiated first in Manual Mode (i.e. without AHCL control) with suspend before low feature (Visit 1).~The AHCL system will be initiated in Auto Mode (i.e. with AHCL control) at Visit 2 with the settings in the below table. The Insulin to Carb ratio (ICR) and the Active Insulin Time (AIT) may be adjusted by the physician during the study. The glucose target may not be adjusted, unless in case of safety concerns. The patients may not adjust system settings without consulting with the physician.~At each visit, the AHCL system data will be downloaded and reviewed by the physician. The patient interaction with the system will be evaluated, included sensor calibration, bolus management (before the meals and for corrections as needed), alarms and Auto Mode exits.